AlphAIAlphAI — Financial news for AI agents
GlobeNewswireSEP 52 min read$AIFF

Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America

KENMORE, N.Y. and MIAMI, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Firefly Neuroscience, Inc. ( "Firefly" ) ( NASDAQ: AIFF ) , an Artificial Intelligence ( "AI" ) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today ...

Original reporting
GlobeNewswire · Inc., Firefly Neuroscience
Published Sep 5, 2025, 11:55 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2025, 12:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$AIFFBullishMed
01

Why it matters

The partnership could accelerate product adoption, improve clinical outcomes, and attract investor interest, positively influencing Firefly's stock performance.

02

Market read

The news is relevant for investors interested in biotech, AI, and healthcare sectors, especially those focusing on neurotechnology.

03

What to watch

Market volatility and broader economic conditions could overshadow sector-specific positives.

Relevance 6/10Timing: Immediate, as the news is recent and pertains to ongoing strategic developments.

Background

Firefly Neuroscience is developing AI solutions for brain health, recently partnering with HealingMaps to expand analytics offerings to clinics across North America.

Company-level read

Ticker impact

$AIFFBullishMedium confidence
Context

Primary focus due to company's involvement in AI solutions for brain health and recent partnership announcement.

Expected impact

Moderate upward movement over the next 1-3 months.

Evidence & confidence

The news indicates strategic growth and market expansion, which are positive signals; however, the impact depends on execution and market reception.

Market effects

Sector

Potential uplift in biotech and AI sectors due to advancements in neurotechnology and healthcare analytics.

Regional

Primarily North American markets, with possible global interest due to the company's NASDAQ listing.

Global

Moderate; depends on international adoption of the new analytics solutions.

Counterpoint

What could challenge this read

The partnership may face integration challenges or delayed adoption, leading to limited short-term impact.

Key entities

  • Company
    Firefly Neuroscience, Inc.

    Developer of AI solutions for neurological and mental health disorders.

  • Partner
    HealingMaps

    Provider of healthcare analytics and clinic management solutions.

Read at source← All news

Related articles

SEP 25
$AIFFHighAI 8/10

AI Stock Firefly Neuroscience (NASDAQ: AIFF) Soars on First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly Neuroscience (NASDAQ: AIFF) stock surged 32.77% after announcing a partnership with NeuroSigma to expand access to the FDA-cleared Monarch eTNS(R) System, a non-drug treatment for pediatric ADHD. The stock traded at $1.58 on high volume. Firefly's Evoke(TM) platform provides AI-powered brain function analytics to clinicians. According to a 2024 study, approximately 7.1 million U.S. children have been diagnosed with ADHD, with nearly one-third receiving no treatment.

investorideas.com2 min
SEP 25
$AIFFHigh

Firefly Hikes on Partnering with NeuroSigma

Firefly Neuroscience (AIFF) and NeuroSigma partnered to promote NeuroSigma's Monarch eTNS System, a non-drug ADHD treatment, through Firefly's Evoke platform network. AIFF shares rose 38.9% to $1.65. According to a 2024 study, 7.1 million U.S. children have ADHD, with many seeking non-medication treatments.

baystreet.ca2 min
OCT 8
$IONQMed

The One Number IonQ Stock Investors Should Watch

IonQ (IONQ) reported a $485M backlog of undelivered orders, up from $122M a year earlier, according to its August 2026 earnings call. The company signed new contracts, including a $300M potential deal with DARPA. Despite growth, IonQ's stock fell 48% over the past year, trading at 61.7x sales. Management raised 2026 revenue guidance to $280M-$290M, excluding SkyWater acquisition.

finance.yahoo.com3 min